Ethclorvynol
Ethclorvynol Brand names, Ethclorvynol Analogs
Ethclorvynol Brand Names Mixture
- No information avaliable
Ethclorvynol Chemical_Formula
C2H8O7P2
Ethclorvynol RX_link
http://www.rxlist.com/cgi/generic2/didronel.htm
Ethclorvynol fda sheet
Ethclorvynol msds (material safety sheet)
Ethclorvynol Synthesis Reference
No information avaliable
Ethclorvynol Molecular Weight
206.028 g/mol
Ethclorvynol Melting Point
No information avaliable
Ethclorvynol H2O Solubility
No information avaliable
Ethclorvynol State
Solid
Ethclorvynol LogP
-2.734
Ethclorvynol Dosage Forms
Solution for injection (50mg/mL); Tablet (200, 400 mg)
Ethclorvynol Indication
For the treatment of symptomatic Paget's disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury.
Ethclorvynol Pharmacology
Etidronate is a first generation (non-nitrogenous) bisphosphonate in the same family as clodronate and tiludronate. Etidronate affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the etidronate that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the kidney. The remainder has a very high affinity for bone tissue, and is rapidly absorbed onto the bone surface. Etidronate has been shown to prevent or delay skeletal-related events and decrease bone pain as well as normalize calcium levels in the presence of hypercalcemia.
Ethclorvynol Absorption
The amount of drug absorbed after an oral dose is approximately 3%.
Ethclorvynol side effects and Toxicity
Clinical experience with acute etidronate overdosage is extremely limited. Decreases in serum calcium following substantial overdosage may be expected in some patients. Signs and symptoms of hypocalcemia also may occur in some of these patients. Some patients may develop vomiting. In one event, an 18-year-old female who ingested an estimated single dose of 4800 to 6000 mg (67 to 100 mg/kg) of etidronate was reported to be mildly hypocalcemic (7 .5 2 mg/ dl) and experienced paresthesia of the fingers.
Ethclorvynol Patient Information
Ethclorvynol Organisms Affected
Humans and other mammals
